Loading...
XSHG600488
Market cap640mUSD
Dec 25, Last price  
4.28CNY
1D
-1.83%
1Q
6.20%
Jan 2017
-31.08%
Name

Tianjin Tianyao Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHG:600488 chart
P/E
39.92
P/S
1.24
EPS
0.11
Div Yield, %
0.23%
Shrs. gr., 5y
—
Rev. gr., 5y
9.27%
Revenues
3.78b
+2.55%
964,176,260661,330,551585,636,292698,959,130876,889,859887,062,3061,128,131,8441,418,381,6611,642,531,4611,480,538,1541,388,919,0081,404,719,8881,206,600,2281,971,716,5252,427,864,5852,915,700,7743,116,847,8223,748,664,5583,688,929,9333,782,826,621
Net income
117m
+534.88%
100,858,18380,803,52644,058,91826,139,16150,223,78765,389,10790,828,63393,198,00398,844,46451,925,70086,583,92278,723,91263,805,667129,808,346153,450,350145,277,87480,575,160108,667,64918,436,815117,052,520
CFO
783m
+19.81%
110,300,224050,721,973162,327,984219,308,547435,133,628116,821,46578,473,75713,227,62384,554,189178,763,589129,501,81263,320,3300189,265,815279,368,978346,884,942316,889,762653,524,527783,008,315
Dividend
Jun 14, 20240.087 CNY/sh
Earnings
Apr 23, 2025

Profile

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
URL
http://www.tjpcty.com/
IPO date
Jun 18, 2001
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,782,827
2.55%
3,688,930
-1.59%
3,748,665
20.27%
Cost of revenue
3,375,004
3,257,346
3,337,271
Unusual Expense (Income)
NOPBT
407,823
431,583
411,394
NOPBT Margin
10.78%
11.70%
10.97%
Operating Taxes
5,567
40,400
Tax Rate
1.36%
9.82%
NOPAT
402,256
431,583
370,995
Net income
117,053
534.88%
18,437
-83.03%
108,668
34.86%
Dividends
(10,882)
(15,312)
(11,000)
Dividend yield
0.20%
0.32%
0.22%
Proceeds from repurchase of equity
(5,780)
BB yield
0.11%
Debt
Debt current
270,365
944,553
1,039,980
Long-term debt
277,112
458,870
367,783
Deferred revenue
144,989
117,699
89,565
Other long-term liabilities
8,773
1,008
1
Net debt
(335,581)
448,534
813,500
Cash flow
Cash from operating activities
783,008
653,525
316,890
CAPEX
(133,148)
Cash from investing activities
(132,122)
Cash from financing activities
(564,848)
92,693
FCF
870,225
894,934
249,825
Balance
Cash
718,856
647,742
232,216
Long term investments
164,202
307,147
362,047
Excess cash
693,917
770,442
406,830
Stockholders' equity
3,198,357
3,430,928
3,489,213
Invested Capital
3,760,514
4,476,000
4,866,899
ROIC
9.77%
9.24%
7.81%
ROCE
9.12%
8.17%
7.73%
EV
Common stock shares outstanding
1,091,887
1,091,887
1,091,887
Price
4.90
11.11%
4.41
-3.92%
4.59
-6.90%
Market cap
5,350,245
11.11%
4,815,220
-3.92%
5,011,760
-6.90%
EV
5,814,414
6,045,083
6,649,095
EBITDA
680,726
688,654
620,190
EV/EBITDA
8.54
8.78
10.72
Interest
36,682
48,182
45,879
Interest/NOPBT
8.99%
11.16%
11.15%